Express Pharma
Home  »  Drug approvals  »  Biocon launches Tacrolimus capsules in US

Biocon launches Tacrolimus capsules in US

It is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ

1 152
Read Article

Biocon announced the launch of Tacrolimus capsules in the US. Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ.

It has been particularly effective in treating patients of renal transplant for more than two decades.

Siddharth Mittal, CEO and MD, Biocon, said, “The launch of Tacrolimus capsules in the US is another milestone for Biocon that reflects our commitment to continually evaluate and expand our portfolio of complex products to serve patients.”

1 Comment
  1. hadil says

    thank you

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Know Importance of using different levels of Controls
Register Now!
close-image